| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
GSTO1-IN-1, a chloroacetamide-containing compound, is a novel and potent glutathione S-transferase omega 1 (GSTO1) inhibitor with an IC50 of 31 nM. Glutathione S-transferase omega 1 (GSTO1) is an atypical GST isoform that is overexpressed in several cancers and has been implicated in drug resistance. Currently, no small-molecule drug targeting GSTO1 is under clinical development. Co-crystal structures of GSTO1 with GSTO1-IN-1 demonstrate covalent binding to the active site cysteine. These potent GSTO1 inhibitor GSTO1-IN-1 suppresses cancer cell growth, enhance the cytotoxic effects of cisplatin and inhibit tumour growth in colon cancer models as single agent. Bru-seq-based transcription profiling unravelled novel roles for GSTO1 in cholesterol metabolism, oxidative and endoplasmic stress responses, cytoskeleton and cell migration.These findings demonstrate the therapeutic utility of GSTO1 inhibitors as anticancer agents and identify the novel cellular pathways under GSTO1 regulation in colorectal cancer.
| ln Vitro |
GSTO1-IN-1 (C1-27) has an IC50 value of 31 nM, which is an effective inhibitor of GSTO1 enzyme activity. When it comes to binding to recombinant proteins and endogenous GSTO1 in a soluble proteomic context, GSTO1-IN-1 also faces competition from 5-chloromethylfluorescein diacetate (CMFDA). A dose-dependent reduction in cell viability was also seen in HCT116 cells treated with GSTO1-IN-1. At submicromolar concentrations, GSTO1-IN-1 prevents HCT116 cell clonal survival [1].
|
|---|---|
| ln Vivo |
GSTO1-IN-1's effects were assessed in a human colon cancer cell line xenograft model in order to determine whether it is effective in vivo. HCT116 xenograft-bearing nude mice received a single dose of GSTO1-IN-1 (20–45 mg/kg). Following a 5-week course of treatment, the tumor growth of mice in the GSTO1-IN-1 treatment group was considerably suppressed (P<0.05) in comparison to the vehicle treatment group. Throughout the course of the trial, mice showed no overt toxicity and generally tolerated treatment with GSTO1-IN-1 up to 45 mg/kg with no discernible side effects or changes in average body weight [1].
|
| References |
| Molecular Formula |
C10H12N2O3SCL2
|
|---|---|
| Molecular Weight |
311.18488
|
| Exact Mass |
309.994
|
| CAS # |
568544-03-6
|
| PubChem CID |
3860347
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.591
|
| LogP |
1.25
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
18
|
| Complexity |
394
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
YEHYODCKTNLFQU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H12Cl2N2O3S/c1-14(2)18(16,17)9-5-7(3-4-8(9)12)13-10(15)6-11/h3-5H,6H2,1-2H3,(H,13,15)
|
| Chemical Name |
2-chloro-N-[4-chloro-3-(dimethylsulfamoyl)phenyl]acetamide
|
| Synonyms |
GSTO1-IN-2; GSTO1 IN2; GSTO1 IN-2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 300 mg/mL (~964.07 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2136 mL | 16.0679 mL | 32.1357 mL | |
| 5 mM | 0.6427 mL | 3.2136 mL | 6.4271 mL | |
| 10 mM | 0.3214 mL | 1.6068 mL | 3.2136 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
 Identification and characterization of C1-27 as a potent GSTO1 inhibitor.Nat Commun.2016 Oct 5;7:13084. |
|---|
 GSTO1 inhibition impedes cancer cell viability.Nat Commun.2016 Oct 5;7:13084. |
 C1-27 inhibits colorectal cancer tumour growthin vivo.Nat Commun.2016 Oct 5;7:13084. |
 C1-27 is a covalent GSTO1 inhibitor.Nat Commun.2016 Oct 5;7:13084. |
|---|
 Analysis of gene expression following C1-27 treatment and GSTO1 knockdown.Nat Commun.2016 Oct 5;7:13084. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA